Dr Peter McCullough On Covid19: Treatment, Vaccines & A Dire Warning For New Zealand
On 27 Aug, 2021 By admin 0 Comments
Health Policy
Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
On 25 Aug, 2021 By admin 0 Comments
August, 2021
Abstract
Background: Reports of waning vaccine-induced immunity against COVID-19 have begun to surface. With that, the comparable long-term protection conferred by previous infection with SARS-CoV-2 remains unclear.
The Economic Effect of the COVID-19 Lockdown in the United States: Was the Cure Worse than the Disease?
On 23 Aug, 2021 By admin 0 Comments
May, 2021
Abstract
COVID-19 is an ongoing global outbreak of coronavirus disease 2019, an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern on January 30, 2020; and a pandemic on March 11, 2020.
Impact of the COVID-19 Pandemic and Policy Responses on Excess Mortality
On 23 Aug, 2021 By admin 0 Comments
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
On 23 Aug, 2021 By admin 0 Comments
August, 2021
Abstract
Background:
Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials.
Areas of uncertainty:
We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection.
Data sources:
Dr. David Martin on Patent System and Over 5,000 Corona Virus Patents
On 20 Aug, 2021 By admin 0 Comments
Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?
On 13 Aug, 2021 By admin 0 Comments
August, 2021
Highlights
- Infection-enhancing antibodies have been detected in symptomatic Covid-19
- Antibody dependent enhancement (ADE) is a potential concern for vaccines
- Enhancing antibodies recognize both the Wuhan strain and Delta variants
- ADE of Delta variants is a potential risk for current vaccines
- Vaccine formulations lacking ADE epitope are suggested
Abstract
Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis
On 13 Aug, 2021 By admin 0 Comments
A TALE OF TWO SCIENTIFIC PARADIGMS: CONFLICTING SCIENTIFIC OPINIONS ON WHAT “FOLLOWING THE SCIENCE” MEANS FOR SARS-COV-2 AND THE COVID-19 PANDEMIC
On 12 Aug, 2021 By admin 0 Comments
August, 2021
DSA ADS Course - 2021
COVID19, Public Policy, Health Policy, Modeling, Model-driven Science, Empirically-driven Science, Lockdowns, Non-pharmaceutical Interventions, NPIs
Discuss 2 paradigms: Model-driven Science vs. Empirically-driven Science
Forecasting for COVID19 has Failed
On 11 Aug, 2021 By admin 0 Comments
June, 2020
DSA ADS Course - 2021
Forecasting, COVID19, John Ioannidis, Public Policy, Health Policy, Causal Inference, Forensic Medicine, Causality, Intuitive Causation, Probabilistic Causation
Forecasting is usually impossible in high causal density environments. Scenario planning with applied probability and adaptation to near real-time data is optimal strategy. Epidemic forecasting is usually a fools errand yet appropriate analysis of experience and historical precedent is helpful.